Related Experiment Video
Updated: Jun 27, 2025
06:09
Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
Published on: July 21, 2023
1.2K
Longitudinal Follow-Up of Fibrosis-4 in Patients at Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease
Jing Cui1, Vincent Di Martino2, Daniel H Solomon1
1Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Summary
Noninvasive liver fibrosis tests, like the fibrosis-4 (FIB-4) score, can predict fibrosis severity. FIB-4 is widely used for monitoring liver disease, including metabolic dysfunction-associated steatotic liver disease (MASLD).
Area of Science:
- Hepatology
- Biomarkers
- Liver Disease Diagnostics
Background:
- Liver biopsy is invasive; noninvasive tests are needed for fibrosis assessment.
- The fibrosis-4 (FIB-4) score was initially developed for HIV/HCV co-infected patients.
- FIB-4 is increasingly used for monitoring liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD).
Purpose of the Study:
- To review the role of noninvasive liver fibrosis tests.
- To highlight the utility of the FIB-4 score in clinical practice.
- To discuss FIB-4's application in MASLD monitoring.
Main Methods:
- Review of existing literature on liver fibrosis tests.
- Analysis of FIB-4 score's application and validation.
- Discussion of clinical relevance in MASLD patients.
Main Results:
- Noninvasive tests show promise in predicting fibrosis severity.
- FIB-4 score is a widely adopted tool for liver fibrosis monitoring.
- FIB-4 aids in managing patients with MASLD.
Conclusions:
- Noninvasive liver fibrosis tests, particularly FIB-4, are valuable tools.
- FIB-4 offers a practical approach to monitoring liver fibrosis.
- Continued research supports the use of FIB-4 in MASLD management.
